Cardiff Oncology, Inc. cotiza a 1.01 USD y tiene una capitalización bursátil de $79M. En los últimos 12 meses ha facturado $508000 con un margen de flujo de caja libre del -6402.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses o…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-0.14 | — | $-0.18 |
| Estimado | $-0.13 | $-0.16 | $-0.16 | $-0.12 |
| Sorpresa | — | +12.5% | — | -50.0% |
| Métrica | CRDF | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -8256.3% | -38.6% | -8217.7% |
| Net Margin | -7732.0% | -33.6% | -7698.5% |
| FCF Margin | -6402.5% | -13.9% | -6388.7% |
| ROE | -101.0% | -40.4% | -60.6% |
| ROA | -74.1% | -32.0% | -42.1% |
| Current Ratio | 3.67 | 2.84 | +0.83 |
| Debt / Equity | — | 0.28 | — |